Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage pharmaceutical company developing potential first in class oncology and CNS therapeutics, today announced that it has appointed Dr. Peter D. Suzdak as its new Chief Executive Officer (CEO). He succeeds Dr. Chang Ahn, who will move into the role of Chief Scientist and will remain as Chairman of the Board.
"We are very excited to have Dr. Suzdak join Rexahn as its new CEO. Dr. Suzdak possesses the experience and stature to lead Rexahn to the next level of growth and development,” said Dr. Chang Ahn, Rexahn’s Chairman of the Board. “Dr. Suzdak’s track record of entrepreneurial success, wide network of industry relationships, and history of building shareholder value will be of great value to Rexahn going forward.”
“Rexahn has tremendous market potential. There are very few clinical stage biopharmaceutical companies that can match Rexahn’s breadth and depth of clinical and preclinical stage assets and extensive intellectual property portfolio. Based on these facts alone, I believe that Rexahn has the potential to create tremendous value for both patients and shareholders alike,” stated Dr. Suzdak. “I am eager to help put Rexahn on a path to significant and sustainable value creation for shareholders. By establishing a market-oriented approach to corporate and product development we can begin to drive the value of Rexahn’s promising drug pipeline.”
Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to that he was co-Founder, founding Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to that he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts